Loading...

Alector

DB:0Z2
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0Z2
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Alector has significant price volatility in the past 3 months.
0Z2 Share Price and Events
7 Day Returns
-15.5%
DB:0Z2
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:0Z2
-10.2%
DE Biotechs
-6%
DE Market
0Z2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alector (0Z2) -15.5% 17.1% - - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 0Z2.
  • No trading data on 0Z2.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

0Z2 Value

 Is Alector undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Alector to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Alector.

DB:0Z2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0Z2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:0Z2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Alector is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0Z2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 237.31 Est @ 92.67% 219.78
2020 391.41 Est @ 64.93% 335.72
2021 569.58 Est @ 45.52% 452.46
2022 751.48 Est @ 31.93% 552.85
2023 919.97 Est @ 22.42% 626.82
2024 1,065.00 Est @ 15.76% 672.03
2025 1,183.25 Est @ 11.1% 691.50
2026 1,276.02 Est @ 7.84% 690.63
2027 1,346.92 Est @ 5.56% 675.16
2028 1,400.24 Est @ 3.96% 650.04
Present value of next 10 years cash flows $5,566.99
DB:0Z2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,400.24 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$18,113.95
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $18,113.95 ÷ (1 + 7.98%)10
$8,409.09
DB:0Z2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $5,566.99 + $8,409.09
$13,976.08
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $13,976.08 / 68.87
$202.93
DB:0Z2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0Z2 represents 0.83035x of NasdaqGS:ALEC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.83035x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 202.93 x 0.83035
€168.50
Value per share (EUR) From above. €168.50
Current discount Discount to share price of €18.66
= -1 x (€18.66 - €168.50) / €168.50
88.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Alector is available for.
Intrinsic value
>50%
Share price is €18.66 vs Future cash flow value of €168.5
Current Discount Checks
For Alector to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Alector's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Alector's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alector's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alector's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0Z2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.62
NasdaqGS:ALEC Share Price ** NasdaqGS (2019-04-18) in USD $22.47
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alector.

DB:0Z2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ALEC Share Price ÷ EPS (both in USD)

= 22.47 ÷ -4.62

-4.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alector is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alector is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alector's expected growth come at a high price?
Raw Data
DB:0Z2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-7.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alector, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alector's assets?
Raw Data
DB:0Z2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-7.08
NasdaqGS:ALEC Share Price * NasdaqGS (2019-04-18) in USD $22.47
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:0Z2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ALEC Share Price ÷ Book Value per Share (both in USD)

= 22.47 ÷ -7.08

-3.18x

* Primary Listing of Alector.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alector has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Alector's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alector has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0Z2 Future Performance

 How is Alector expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alector expected to grow at an attractive rate?
  • Unable to compare Alector's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Alector's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Alector's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0Z2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0Z2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -7.7%
DB:0Z2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 37%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0Z2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0Z2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 250 -9 1
2022-12-31 50 -187 1
2021-12-31 50 -167 1
2020-12-31 50 -116 2
2019-12-31 45 -85 2
DB:0Z2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 28 127 -52
2018-09-30 22 143 -45
2018-06-30 15 159 -39
2018-03-31 9 70 -36
2017-12-31 4 -18 -32
2016-12-31 0 -13 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alector is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Alector's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0Z2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Alector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0Z2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.11 -0.11 -0.11 1.00
2022-12-31 -2.24 -2.24 -2.24 1.00
2021-12-31 -2.25 -2.25 -2.25 1.00
2020-12-31 -1.52 -1.06 -1.98 2.00
2019-12-31 -1.23 -0.99 -1.47 2.00
DB:0Z2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.62
2018-09-30 -4.07
2018-06-30 -3.79
2018-03-31 -3.68
2017-12-31 -3.55
2016-12-31 -2.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alector will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Alector's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alector has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0Z2 Past Performance

  How has Alector performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alector's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alector does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Alector's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alector's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alector's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0Z2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 27.68 -52.25 11.93
2018-09-30 21.59 -44.65 9.90
2018-06-30 15.24 -39.37 9.23
2018-03-31 9.49 -35.92 7.87
2017-12-31 3.74 -32.48 6.50
2016-12-31 0.42 -15.11 1.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alector has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alector has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alector improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alector's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alector has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0Z2 Health

 How is Alector's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alector's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alector is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alector's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alector's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Alector has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alector Company Filings, last reported 3 months ago.

DB:0Z2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 113.12 0.00 290.41
2018-09-30 127.39 0.00 308.69
2018-06-30 78.17 0.00 268.10
2018-03-31 78.17 0.00 268.10
2017-12-31 25.45 0.00 32.45
2016-12-31 52.58 0.00 50.84
  • Alector has no debt.
  • Alector has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Alector has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Alector has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -103.8% per year.
X
Financial health checks
We assess Alector's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alector has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0Z2 Dividends

 What is Alector's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alector dividends. Estimated to be 0% next year.
If you bought €2,000 of Alector shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alector's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alector's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0Z2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0Z2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alector has not reported any payouts.
  • Unable to verify if Alector's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alector's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alector has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alector's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alector's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alector afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alector has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0Z2 Management

 What is the CEO of Alector's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arnon Rosenthal
COMPENSATION $5,453,983
AGE 63
TENURE AS CEO 6.3 years
CEO Bio

Dr. Arnon Rosenthal, Ph.D., co-founded of Alector LLC in 2013 and serves as its Chief Executive Officer, President and Director since 2013. He served a Chief Scientific Officer of Alector LLC. Dr. Rosenthal co-founded Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served as a member of the board of directors, including as Chairman from August 2011 February 2017. He co-founded Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006) in October 2001 and served as President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr. Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff Scientist and was appointed as a permanent member of Genentech’s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. Dr. Rosenthal is a Visiting Professor of the Department of Anatomy at the University of California San Francisco and a Member of the Scientific Advisory Board of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He is a Member of the NIH Advisory Committee on Parkinson's Disease and Neuronal Repair. He is a Leader in the field of neurological disease, publishing over 70 articles on the topic. Dr. Rosenthal holds a Ph.D. in biology from the Hebrew University of Jerusalem.

CEO Compensation
  • Arnon's compensation has increased whilst company is loss making.
  • Arnon's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alector management team in years:

2.4
Average Tenure
52
Average Age
  • The tenure for the Alector management team is about average.
Management Team

Tillman Gerngross

TITLE
Co-Founder & Chairman
COMPENSATION
$25K
AGE
54
TENURE
6.3 yrs

Arnon Rosenthal

TITLE
Co-Founder
COMPENSATION
$5M
AGE
63
TENURE
6.3 yrs

Robert Paul

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
50
TENURE
2.5 yrs

Robert King

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
55
TENURE
2.3 yrs

Asa Abeliovich

TITLE
Co-Founder

Calvin Yu

TITLE
Vice President of Finance
AGE
42
TENURE
1.8 yrs

Stephanie Yonker

TITLE
Vice President of Legal

Sabah Oney

TITLE
Chief Business Officer
AGE
35
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Alector board of directors in years:

6.3
Average Tenure
62.5
Average Age
  • The tenure for the Alector board of directors is about average.
Board of Directors

Arnon Rosenthal

TITLE
Co-Founder
COMPENSATION
$5M
AGE
63
TENURE
6.3 yrs

Carl Gordon

TITLE
Director
AGE
53

Tillman Gerngross

TITLE
Co-Founder & Chairman
COMPENSATION
$25K
AGE
54
TENURE
6.3 yrs

Richard Scheller

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$583K
AGE
65
TENURE
0.5 yrs

Louis Lavigne

TITLE
Lead independent director
AGE
69
TENURE
0.5 yrs

Terry McGuire

TITLE
Director
AGE
62
TENURE
6.3 yrs

Adam Boxer

TITLE
Member of Scientific Advisory Board

Marco Colonna

TITLE
Member of Scientific Advisory Board

Stephen Hauser

TITLE
Member of Scientific Advisory Board

Michael Heneka

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Feb 19 Buy OrbiMed Advisors, L.L.C. Company 11. Feb 19 11. Feb 19 88,300 €16.84 €1,487,281
12. Feb 19 Buy OrbiMed Advisors, L.L.C. Company 11. Feb 19 11. Feb 19 411,700 €16.84 €6,934,469
X
Management checks
We assess Alector's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alector has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0Z2 News

Simply Wall St News

0Z2 Company Info

Description

Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer’s disease. The company’s preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer’s disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.

Details
Name: Alector, Inc.
0Z2
Exchange: DB
Founded: 2013
$1,376,080,718
68,871,792
Website: http://alector.com
Address: Alector, Inc.
151 Oyster Point Boulevard,
Suite 300,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ALEC Common Stock Nasdaq Global Select US USD 07. Feb 2019
DB 0Z2 Common Stock Deutsche Boerse AG DE EUR 07. Feb 2019
Number of employees
Current staff
Staff numbers
78
Alector employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:16
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.